An interventional study of Cocoa and Placebo in Diabetic Neuropathies, sponsored by Anahuac University. Completed at 3 sites in Mexico. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-05-01.
Sponsored by Anahuac University · Not applicable, Interventional, and Treatment
Type 2 diabetes mellitus is a high incidence disease in Mexico and is associated with the development of chronic degenerative complications such as diabetic neuropathy. The latter manifests itself as a set of disorders that occur as a consequence of a chronic hyperglycemic state that can induce oxidative stress and inflammation, resulting in damage to the autonomic and peripheral nervous system. In Mexico, it has been reported that this complication usually occurs between 29% and 90% of patients with diabetes.
Cocoa is a food with a high content of flavonoids, which are phenolic compounds with antioxidant and anti-inflammatory effects. Additionally, its consumption has been associated with a decrease in hyperglycemia and insulin resistance, improvement in mitochondrial function, and, based on the above, an effect on diabetic complications has been suggested; This has been demonstrated in in vivo and in vitro models, but not in the human population.
Once the symptoms of diabetic neuropathy have started, palliative treatments are prescribed, and to date there are no pharmacological compounds that have been shown to reverse the consequences of diabetic peripheral and autonomic neuropathy. Additionally, clinical trials of compounds with antioxidant properties have only performed subjective evaluations based on questionnaires on the perception of the improvement of diabetic neuropathy and some biochemical markers or nerve conduction tests, however, the results shown have not been conclusive.
This is why a double-blind, randomized controlled clinical trial is proposed, with the objective of evaluating the effect of cocoa supplementation in patients with type 2 diabetes mellitus and peripheral and autonomic diabetic neuropathy on a) the biochemical profile, which includes the evaluation of the glycemic and lipid profile, quantification of pro-inflammatory cytokines and oxidative stress markers; b) the clinical profile through the application of standardized questionnaires, anthropometric measurements and blood pressure, and c) somatosensory processing through the paired pulse H reflex test.
The hypothesis of this study is that cocoa supplementation will have a beneficial effect on the biochemical and clinical profile and somatosensory processing of peripheral and autonomic diabetic neuropathy.
Type 2 diabetes mellitus (T2DM) is a high incidence disease in Mexico and is associated with the development of chronic degenerative complications such as diabetic neuropathy. The latter manifests itself as a set of disorders that occur as a consequence of a chronic hyperglycemic state that can induce oxidative stress and inflammation, resulting in damage to the autonomic and peripheral nervous system. In Mexico, it has been reported that this complication usually occurs between 29% and 90% of patients with diabetes.
Cocoa is a food with a high content of flavonoids, which are phenolic compounds with antioxidant and anti-inflammatory effects. Additionally, its consumption has been associated with a decrease in hyperglycemia and insulin resistance, improvement in mitochondrial function, and, based on the above, an effect on diabetic complications has been suggested; This has been demonstrated in in vivo and in vitro models, but not in the human population.
Once the symptoms of diabetic neuropathy have started, palliative treatments are prescribed, and to date there are no pharmacological compounds that have been shown to reverse the consequences of diabetic peripheral and autonomic neuropathy. Additionally, clinical trials of compounds with antioxidant properties have only performed subjective evaluations based on questionnaires on the perception of the improvement of diabetic neuropathy and some biochemical markers or nerve conduction tests, however, the results shown have not been conclusive.
This is why a double-blind, randomized controlled clinical trial is proposed, with the objective of evaluating the effect of cocoa supplementation in patients with type 2 diabetes mellitus and peripheral and autonomic diabetic neuropathy on a) the biochemical profile, which includes the evaluation of the glycemic and lipid profile, quantification of pro-inflammatory cytokines and oxidative stress markers; b) the clinical profile through the application of standardized questionnaires, anthropometric measurements and blood pressure, and c) somatosensory processing through the paired pulse H reflex test. Hypothesis: The hypothesis of this study is that cocoa supplementation will have a beneficial effect on the biochemical and clinical profile and somatosensory processing of peripheral and autonomic diabetic neuropathy. Statistical analysis: For the evaluation of the intragroup variables, a statistical analysis will be carried out with ANOVA for repeated samples with Tukey's post hoc, or, where appropriate, Friedman with Dunn's post hoc, as well as Student's t for dependent groups, or in its case, with Wilcoxon. The intergroup comparison will be made with Student's T for independent samples, or if applicable, with Mann Whitney's U, considering p \<0.05 as statistical significance and using the statistical software GraphPad Prism version 5.
The H reflex test will be performed by electrical stimulation through disposable surface electrodes connected to a constant current bipolar electrical stimulator (Digitimer DS8R). The recording of the electrophysiological signals will be carried out using surface electrodes connected to the signal acquisition and amplification system (LabChart and PowerLab 8/35, ADInstruments). The signals obtained will be sampled at 10 kilohertz (KHz) with a 0.5- 500 Hz band-pass filter. The signals will be stored in a computer for later analysis.
The placement of electrodes for stimulation will be carried out as follows: the active electrode (anode) at the level of the Achilles tendon, the positive electrode (cathode) above the inverted "v" between the calf muscles (gastrocnemius). Subsequently, the reference electrode will be placed at the level of the gastrocnemius heads. It will be stimulated behind the knee where the tibial nerve has its anatomical path.
The test will start with an intensity of 0 milliamp (mA) and then pulses will be given every 0.5 millivolts (mV) until the evoked potential (H reflex) is observed in a consistent and clearly identifiable way as a function of latency (35-45 ms). The electrical stimulus consists of the application of 1 square pulse (1 ms duration each pulse) every 10 seconds (10 pulses in total). The maximum intensity of the applied current will be according to the sensitivity and tolerance of the individual in both lower limbs during the tests on the sensory and motor nerves. The applied electrical pulse should not cause a painful sensation, but it can cause a tingling sensation. The test will be suspended if the individual reports pain or does not wish to continue with the research protocol. The "H" reflex test will be done in two parts. The first part of the protocol consists of determining the stimulus intensity vs. amplitude of motor responses from the appearance of the "M" wave and the "H" wave, for which the electric current will be increased in steps of 0.5 µA until the appearance of the waves. For this part, only one electrical pulse (1 ms duration) will be given every 10 seconds. The intensity of electrical current that will be used for the second part of the protocol will be that whose value in the amplitude curve of the H wave-electrical current intensity reaches 60% of the maximum amplitude. This stimulation value guarantees the reproducibility and minimum variability of this wave, which also prevents muscle contraction that contaminates the electrical register. The second part constitutes the paired electrical stimulation test in which two electrical pulses (1 ms in duration) will be produced at different frequencies between the pulses: 0.1, 1, 5 and 10 Hz. The interval between the paired pulses will be 10 s, until completing 10 series.
The electrophysiological recordings will be analyzed with the Clampfit 10.0 software. The latency and amplitude of the evoked potentials H1 and H2 will be determined for each electrical pulse and at all stimulation frequencies, taking the stimulus artifact as a reference. Subsequently, the ratio of the amplitude of the paired H2/H1 pulses will be determined to establish the modulation of spinal excitability. A ratio ≥0.6 for any stimulation frequency will be considered as an indicator of dysfunction in somatosensory processing according to Marshall et al.
538 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.
This study's enrollment of 39 is below the median of 68 across 448 interventional studies indexed under Diabetic Neuropathies.
Browse Diabetic Neuropathies studies →Anahuac University is the lead sponsor of 10 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diet for patients with diabetes + 4 capsules of cocoa powder, 500 mg each, daily for 12 weeks.
Dietary Supplement: Cocoa
Diet for patients with diabetes + 4 capsules of methylcellulose 500 mg each, daily for 12 weeks.
Other: Placebo
Each capsule of cocoa powder contains 12.5 mg of flavonoids, providing a total of 50 mg per day.
Each capsule contains 500 mg of methylcellulose
Toronto Clinical Scoring System (TCSS)
It is a system of clinical evaluations carried out by the researcher to identify peripheral neuropathy, assigning a score to symptomatology, reflexes and sensory tests. For the purposes of this study, the total score, i.e., the sum of all units on the scale, is reported. The minimum score that can be obtained is 0 points, while the maximum is 19 points. This means that the higher the score, the greater the severity (no grades were established based on the severity of the neuropathy). For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline and after 12 weeks
Rate-dependent Depression of the H-reflex
Rate-dependent depression (RDD) is a measure of change in amplitude of the Hoffman (H) reflex over consecutive stimulations. Rate-dependent depression is impaired after disinhibition of spinal sensory processing caused by spinal cord injury. For the purposes of this study, the ratio of the amplitude of the pulses Hn/H1 ≥ 0.5 for stimulation frequencies 1, 5 and 10 Hz, was considered as an indicator of dysfunction in somatosensory processing. In healthy subjects, the ratio of the amplitude of the pulses Hn/H1 is expected to be \<0.5. Each subject received 5 pulses for each stimulation frequency, and the average for each subject was determined. The group average was then obtained for each stimulation frequency (1, 5, and 10 Hz). For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline and after 12 weeks
BEST Questionnaire
The questionnaire includes 4 questions that refer to gastrointestinal symptoms. This questions are measured in a scale from 1 (better health status) to 5 (worse health status) and it is related to gastrointestinal autonomic diabetic neuropathy. Final score: Minimum is 4 points (better health status) and maximum is 19 points (worse health status). For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline, after 4, 8 and 12 weeks
Bristol Stool Form Scale
It is composed of categories that include an image and an explanation, ranging from 1 to 7, being 1 separate hard pieces, which pass with difficulty and 7 watery stools. It is related to gastrointestinal autonomic diabetic neuropathy. The reported outcomes are the percentage of participants who had altered bristol stool form scale, that is, participants who were in categories 1, 2, 5, 6 and 7.
Time frame: At baseline and 12 weeks
Weight
Weight of an individual in kg determined by the scale. The measurement is done without shoes and with as little clothing as possible. The subject must be placed in the center and remain still during the measurement. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline, after 4, 8 and 12 weeks
Waist Circumference
Waist circumference in cm: The measuring tape is placed in a horizontal plane around the waist, taking the midaxillary line as a reference, locating the midpoint between the lower costal margin and the highest lateral border of the iliac crest. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline, after 4, 8 and 12 weeks
Waist-to-Height Ratio
It is obtained by dividing the waist circumference in cm by the height in cm, with a result of ≥ 0.5 indicating an increased risk for cardiometabolic disease. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline, after 4, 8 and 12 weeks
Abdominal Circumference
Abdominal circumference in cm: The top of the hip bone and the top of the right iliac crest are located and the measuring tape is placed horizontally around the abdomen, at the level of the iliac crest, at the end of a normal expiration. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline, after 4, 8 and 12 weeks
Systolic Blood Pressure
A sphygmomanometer is used to obtain blood pressure with the technique specified in the Clinical Practice Guidelines for the diagnosis and treatment of arterial hypertension at the first level of care, it is measured in mmHg. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline, after 4, 8 and 12 weeks
Diastolic Blood Pressure
A sphygmomanometer is used to obtain blood pressure with the technique specified in the Clinical Practice Guidelines for the diagnosis and treatment of arterial hypertension at the first level of care, it is measured in mmHg. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline, after 4, 8 and 12 weeks
Glucose
Blood glucose concentration and is measured as mg/dL. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline and after 12 weeks
Glycated Hemoglobin A1c
Value of the fraction of hemoglobin that has glucose attached and is reported in percentage (%). For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline and after 12 weeks
Triglycerides
Blood triglycerides concentration and is measured as mg/dL. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline and after 12 weeks
High-density Lipoprotein Cholesterol
Blood high-density lipoprotein cholesterol concentration and is measured as mg/dL. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline and after 12 weeks
Triglycerides/HDL Ratio
It is obtained after dividing the serum concentration of triglycerides in mg/dL by the serum concentration of HDL in mg/dL. It does not have units. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline and after 12 weeks
Low-density Lipoprotein Cholesterol
Blood low-density lipoprotein cholesterol concentration and is measured as mg/dL. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline and after 12 weeks
Neutrophil/Lymphocyte Ratio
It is obtained by dividing the serum concentration of the absolute number of neutrophils by the serum concentration of the absolute number of lymphocytes. Without unit. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline and after 12 weeks
Diabetes 39 Instrument
It is a self-administered instrument that allows patients to describe how their QOL was affected during the previous month in five domains: energy and mobility (15 questions), diabetes control (12 questions), anxiety and worry (4 questions), social impact (5 questions), and sexual behavior (3 questions). Responses are scored on a seven-point scale that ranged from "not affected at all" (score = 1) to "extremely affected" (score = 7). All responses are summed and it is applied a linear transformation to a 0-100 scale. Lower scores indicated a better QOL. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
Time frame: At baseline and after 12 weeks
| Milestone | Intervention Group | Control Group |
|---|---|---|
| Started | 20 | 19 |
| Completed | 16 | 17 |
| Not completed | 4 | 2 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Organizational problems when attending appointments | 1 | 0 |
It is a system of clinical evaluations carried out by the researcher to identify peripheral neuropathy, assigning a score to symptomatology, reflexes and sensory tests. For the purposes of this study, the total score, i.e., the sum of all units on the scale, is reported. The minimum score that can be obtained is 0 points, while the maximum is 19 points. This means that the higher the score, the greater the severity (no grades were established based on the severity of the neuropathy). For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| Score on a scale | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | -2.63 ± 2.24 | -1.84 ± 2.77 |
| Baseline total score | 9.31 ± 3.98 | 6.89 ± 3.47 |
| Final total score | 6.68 ± 4.41 | 5.05 ± 2.91 |
Rate-dependent depression (RDD) is a measure of change in amplitude of the Hoffman (H) reflex over consecutive stimulations. Rate-dependent depression is impaired after disinhibition of spinal sensory processing caused by spinal cord injury. For the purposes of this study, the ratio of the amplitude of the pulses Hn/H1 ≥ 0.5 for stimulation frequencies 1, 5 and 10 Hz, was considered as an indicator of dysfunction in somatosensory processing. In healthy subjects, the ratio of the amplitude of the pulses Hn/H1 is expected to be \<0.5. Each subject received 5 pulses for each stimulation frequency, and the average for each subject was determined. The group average was then obtained for each stimulation frequency (1, 5, and 10 Hz). For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| Ratio | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 for 1 Hz | 0.13 ± 0.36 | 0.01 ± 0.28 |
| Baseline 1 Hz mean | 0.87 ± 0.35 | 0.88 ± 0.33 |
| Final 1 Hz mean | 0.99 ± 0.28 | 0.89 ± 0.16 |
| Change from baseline at Week 12 for 5 Hz | -0.02 ± 0.51 | -0.03 ± 0.30 |
| Baseline 5 Hz mean | 0.91 ± 0.67 | 0.71 ± 0.38 |
| Final 5 Hz mean | 0.89 ± 0.21 | 0.65 ± 0.27 |
| Change from baseline at Week 12 for 10 Hz | 0.13 ± 0.28 | -0.06 ± 0.20 |
| Baseline 10 Hz mean | 0.56 ± 0.47 | 0.71 ± 0.42 |
| Final 10 Hz mean | 0.72 ± 0.25 | 0.62 ± 0.30 |
The questionnaire includes 4 questions that refer to gastrointestinal symptoms. This questions are measured in a scale from 1 (better health status) to 5 (worse health status) and it is related to gastrointestinal autonomic diabetic neuropathy. Final score: Minimum is 4 points (better health status) and maximum is 19 points (worse health status). For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| score on a scale | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | -1.45 ± 2.62 | -2.21 ± 2.59 |
| Baseline total score | 9.35 ± 2.75 | 9.05 ± 2.77 |
| Final total score | 7.9 ± 2.67 | 6.84 ± 2.6 |
It is composed of categories that include an image and an explanation, ranging from 1 to 7, being 1 separate hard pieces, which pass with difficulty and 7 watery stools. It is related to gastrointestinal autonomic diabetic neuropathy. The reported outcomes are the percentage of participants who had altered bristol stool form scale, that is, participants who were in categories 1, 2, 5, 6 and 7.
| percentage of participants | Intervention Group | Control Group |
|---|---|---|
| Baseline altered bristol stool scale form | 40 | 57.8 |
| Final altered bristol stool scale form | 30 | 52.6 |
Weight of an individual in kg determined by the scale. The measurement is done without shoes and with as little clothing as possible. The subject must be placed in the center and remain still during the measurement. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| kg | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | 0.38 ± 2.72 | -0.42 ± 2.18 |
| Baseline | 73.5 ± 14.1 | 82.8 ± 13.8 |
| Week 4 | 74.4 ± 14.8 | 82.5 ± 13.9 |
| Week 8 | 74.1 ± 14.7 | 83 ± 13.7 |
| Final | 73.8 ± 14.6 | 82.4 ± 13.9 |
Waist circumference in cm: The measuring tape is placed in a horizontal plane around the waist, taking the midaxillary line as a reference, locating the midpoint between the lower costal margin and the highest lateral border of the iliac crest. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| cm | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | -0.8 ± 2.19 | -1.38 ± 4.11 |
| Baseline | 96.7 ± 7.49 | 103 ± 13.1 |
| Week 4 | 96.5 ± 7.08 | 103 ± 11.7 |
| Week 8 | 96 ± 7.33 | 103 ± 12 |
| Final | 95.9 ± 7.28 | 102 ± 12 |
It is obtained by dividing the waist circumference in cm by the height in cm, with a result of ≥ 0.5 indicating an increased risk for cardiometabolic disease. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| Ratio | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | -0.00 ± 0.01 | -0.00 ± 0.02 |
| Baseline | 0.6 ± 0.04 | 0.64 ± 0.09 |
| Week 4 | 0.6 ± 0.04 | 0.64 ± 0.08 |
| Week 8 | 0.6 ± 0.04 | 0.64 ± 0.09 |
| Final | 0.6 ± 0.04 | 0.63 ± 0.09 |
Abdominal circumference in cm: The top of the hip bone and the top of the right iliac crest are located and the measuring tape is placed horizontally around the abdomen, at the level of the iliac crest, at the end of a normal expiration. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| cm | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | -0.75 ± 2.45 | -1.02 ± 3.07 |
| Baseline | 100 ± 9.31 | 106 ± 11.4 |
| Week 4 | 100 ± 9.26 | 105 ± 11.7 |
| Week 8 | 99.9 ± 9.27 | 105 ± 12 |
| Final | 99.4 ± 9.01 | 104 ± 12.1 |
A sphygmomanometer is used to obtain blood pressure with the technique specified in the Clinical Practice Guidelines for the diagnosis and treatment of arterial hypertension at the first level of care, it is measured in mmHg. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| mmHg | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | -3.7 ± 11 | -3.78 ± 14.8 |
| Baseline | 126 ± 14.6 | 127 ± 15.5 |
| Week 4 | 125 ± 13.5 | 130 ± 17.2 |
| Week 8 | 122 ± 12.2 | 125 ± 9.7 |
| Final | 122 ± 14.2 | 124 ± 11.7 |
A sphygmomanometer is used to obtain blood pressure with the technique specified in the Clinical Practice Guidelines for the diagnosis and treatment of arterial hypertension at the first level of care, it is measured in mmHg. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| mmHg | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | -2.32 ± 7.57 | -2.36 ± 10.1 |
| Baseline | 79.9 ± 8.23 | 78.1 ± 7.98 |
| Week 4 | 78.7 ± 8.78 | 79 ± 7.77 |
| Week 8 | 79.8 ± 9.1 | 76.6 ± 7.13 |
| Final | 77.6 ± 9.96 | 75.7 ± 7.97 |
Blood glucose concentration and is measured as mg/dL. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| mg/dL | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | -17 ± 42.8 | -38.1 ± 55.9 |
| Baseline mg/dL | 169 ± 62.6 | 195 ± 85.7 |
| Final mg/dL | 152 ± 58.4 | 157 ± 63.6 |
Value of the fraction of hemoglobin that has glucose attached and is reported in percentage (%). For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| percentage of glycated hemoglobin | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | -0.17 ± 1.09 | -0.27 ± 0.60 |
| Baseline % of glycated hemoglobin | 7.82 ± 1.9 | 8.28 ± 2.02 |
| Final % of glycated hemoglobin | 7.72 ± 1.5 | 8 ± 2.04 |
Blood triglycerides concentration and is measured as mg/dL. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| mg/dL | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | -4.96 ± 60.2 | -13.9 ± 44.6 |
| Baseline mg/dL | 182 ± 81.4 | 179 ± 58.8 |
| Final mg/dL | 177 ± 78.8 | 165 ± 52.1 |
Blood high-density lipoprotein cholesterol concentration and is measured as mg/dL. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| mg/dL | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | -0.86 ± 3.71 | 2.18 ± 6.23 |
| Baseline mg/dL | 37.8 ± 9.52 | 38.2 ± 9.12 |
| Final mg/dL | 36.9 ± 7.5 | 40.4 ± 6.26 |
It is obtained after dividing the serum concentration of triglycerides in mg/dL by the serum concentration of HDL in mg/dL. It does not have units. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| Ratio | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | -0.02 ± 1.98 | -0.74 ± 2.13 |
| Baseline | 5.12 ± 2.84 | 4.99 ± 2.13 |
| Final | 5.1 ± 2.9 | 4.25 ± 1.31 |
Blood low-density lipoprotein cholesterol concentration and is measured as mg/dL. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| mg/dL | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | 8.88 ± 22.1 | 4.15 ± 18.1 |
| Baseline mg/dL | 112 ± 31.8 | 108 ± 31.3 |
| Final mg/dL | 121 ± 35.2 | 112 ± 34.7 |
It is obtained by dividing the serum concentration of the absolute number of neutrophils by the serum concentration of the absolute number of lymphocytes. Without unit. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| Ratio | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | -0.09 ± 0.77 | 0.15 ± 0.45 |
| Baseline | 1.96 ± 0.86 | 1.76 ± 0.55 |
| Final | 1.87 ± 1.07 | 1.92 ± 0.61 |
It is a self-administered instrument that allows patients to describe how their QOL was affected during the previous month in five domains: energy and mobility (15 questions), diabetes control (12 questions), anxiety and worry (4 questions), social impact (5 questions), and sexual behavior (3 questions). Responses are scored on a seven-point scale that ranged from "not affected at all" (score = 1) to "extremely affected" (score = 7). All responses are summed and it is applied a linear transformation to a 0-100 scale. Lower scores indicated a better QOL. For the data represented in the row "Change from baseline at Week 12", it is the delta of the final measurement vs. the initial measurement, that is, the final measurement minus the baseline measurement.
| score on a scale | Intervention Group | Control Group |
|---|---|---|
| Change from baseline at Week 12 | -9.19 ± 11.6 | -5.26 ± 19 |
| Baseline total score | 43.4 ± 26.8 | 35.6 ± 22.6 |
| Final total score | 34.2 ± 25.8 | 30.4 ± 24.5 |
Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intervention Group | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| Control Group | 0/19 (0%) | 0/19 (0%) | 0/19 (0%) |
| Age, Continuous(years) | Intervention Group | Control Group | Total |
|---|---|---|---|
| Mean | 53.6 ± 8.67 | 53.7 ± 6.34 | 53.7 ± 7.52 |
| Sex: Female, Male(Participants) | Intervention Group | Control Group | Total |
|---|---|---|---|
| Female | 10 | 12 | 22 |
| Male | 10 | 7 | 17 |
| Race and Ethnicity Not Collected(Participants) | Intervention Group | Control Group | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Intervention Group | Control Group | Total |
|---|---|---|---|
| Mexico | 20 | 19 | 39 |
| Toronto Clinical Scoring System(units on a scale) | Intervention Group | Control Group | Total |
|---|---|---|---|
| Mean | 9.31 ± 3.98 | 6.89 ± 3.47 | 8.10 ± 3.88 |
PDFs hosted by the registry, ClinicalTrials.gov.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cocoa bean
Anahuac University